Non-profit RD Fund invests in therapeutic companies for breakthroughs in retinal degeneration treatment.
Location
Raleigh, NC, US
Founded
2018
The RD Fund, a non-profit subsidiary of the Foundation Fighting Blindness, focuses on accelerating treatments for retinal degenerations through mission-related investments in therapeutic companies. Their portfolio spans various stages, from seed to Series B rounds, with investments primarily in biotechnology and pharmaceutical firms developing innovative therapies for retinal diseases.
Notable portfolio companies include Amber Bio, Atsena Therapeutics, and SalioGen Therapeutics. The fund's unique value proposition lies in its non-profit status and direct connection to the Foundation Fighting Blindness, allowing it to leverage scientific expertise and patient insights to support its portfolio companies in advancing treatments for retinitis pigmentosa, age-related macular degeneration, and Usher syndrome.
RD Fund - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies7
Current Portfolio Count7
Top Investment Stages
Series B3 (42.9%)
Seed2 (28.6%)
Series A2 (28.6%)
Stage Mix
Series B 43%Seed 29%Series A 29%
Concentration shown as share of disclosed investments by stage.